[go: up one dir, main page]

CL2008003549A1 - Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes. - Google Patents

Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.

Info

Publication number
CL2008003549A1
CL2008003549A1 CL2008003549A CL2008003549A CL2008003549A1 CL 2008003549 A1 CL2008003549 A1 CL 2008003549A1 CL 2008003549 A CL2008003549 A CL 2008003549A CL 2008003549 A CL2008003549 A CL 2008003549A CL 2008003549 A1 CL2008003549 A1 CL 2008003549A1
Authority
CL
Chile
Prior art keywords
glucocorticoid
eczema
rhinitis
throat
asthma
Prior art date
Application number
CL2008003549A
Other languages
English (en)
Inventor
Alan Glossop Paul
Simon Millan David
Anthony Price David
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003549(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CL2008003549A1 publication Critical patent/CL2008003549A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de glucocorticoides; procedimientos de preparación; composición farmacéutica; combinación farmacéutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
CL2008003549A 2007-11-30 2008-11-28 Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes. CL2008003549A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99135407P 2007-11-30 2007-11-30
US5724108P 2008-05-30 2008-05-30
US7955508P 2008-07-10 2008-07-10

Publications (1)

Publication Number Publication Date
CL2008003549A1 true CL2008003549A1 (es) 2009-11-20

Family

ID=40427125

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003549A CL2008003549A1 (es) 2007-11-30 2008-11-28 Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.

Country Status (32)

Country Link
US (2) US8822439B2 (es)
EP (1) EP2225256B1 (es)
JP (1) JP4686650B2 (es)
KR (1) KR101295998B1 (es)
CN (1) CN101878221B (es)
AP (1) AP2010005267A0 (es)
AR (1) AR069490A1 (es)
AU (1) AU2008331187B2 (es)
BR (1) BRPI0820447A2 (es)
CA (1) CA2706180C (es)
CL (1) CL2008003549A1 (es)
CO (1) CO6280401A2 (es)
CR (1) CR11393A (es)
DK (1) DK2225256T3 (es)
DO (1) DOP2010000161A (es)
EA (1) EA201070535A1 (es)
EC (1) ECSP10010209A (es)
ES (1) ES2399945T3 (es)
GT (1) GT201000153A (es)
IL (1) IL205356A0 (es)
MA (1) MA31867B1 (es)
MX (1) MX2010005861A (es)
NI (1) NI201000090A (es)
NZ (1) NZ585434A (es)
PA (1) PA8805801A1 (es)
PE (1) PE20091072A1 (es)
SV (1) SV2010003580A (es)
TN (1) TN2010000230A1 (es)
TW (1) TW200930378A (es)
UY (1) UY31496A1 (es)
WO (1) WO2009069032A2 (es)
ZA (1) ZA201003439B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524057B1 (en) * 2010-01-15 2016-03-30 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
EP2686333A2 (en) * 2011-03-15 2014-01-22 Chiesi Farmaceutici S.p.A. Isoxazolidine derivatives
GEP201606566B (en) * 2011-03-15 2016-11-10 Chiesi Farma Spa Isoxazolidine derivatives
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
EP3431141B1 (en) * 2013-03-15 2021-12-08 Aprecia Pharmaceuticals LLC Three-dimensional printing method
EP3244893A4 (en) 2015-02-18 2019-01-09 Parion Sciences, Inc. SODIUM CHANNEL BLOCKER FOR SKIN DISEASES
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EP3901162A1 (en) 2016-06-02 2021-10-27 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
RS63581B1 (sr) 2017-10-05 2022-10-31 Fulcrum Therapeutics Inc Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju lečenja fshd
BR112020010694A2 (pt) * 2017-12-01 2020-11-10 Abbvie Inc. agonista de receptor de glicocorticoides e imunoconjugados do mesmo
SG11202004865SA (en) * 2017-12-01 2020-06-29 Abbvie Inc Anti-cd40 antibody drug conjugates
US20210024628A1 (en) 2018-03-22 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
CN109651474A (zh) * 2019-01-20 2019-04-19 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙的新的制备方法
CN109734763A (zh) * 2019-01-20 2019-05-10 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙产品的制备方法
CN109575097A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙产品的新的制备方法
CN109575095A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙的制备方法
AR125084A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
US20240307415A1 (en) * 2021-06-24 2024-09-19 Jiangsu Simcere Pharmaceutical Co., Ltd. Steroid compound, and pharmaceutical composition thereof and use thereof
US20250002527A1 (en) * 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
WO2023245106A1 (en) 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
WO2004037197A2 (en) 2002-10-24 2004-05-06 Goldstein Jay A Antifungal formulations
WO2005044759A2 (en) * 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalization process for preparation of steroid compounds
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US20050227927A1 (en) 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis

Also Published As

Publication number Publication date
DK2225256T3 (da) 2013-03-11
CR11393A (es) 2010-05-19
WO2009069032A3 (en) 2009-08-06
CA2706180A1 (en) 2009-06-04
AU2008331187B2 (en) 2014-04-03
WO2009069032A2 (en) 2009-06-04
IL205356A0 (en) 2010-12-30
PE20091072A1 (es) 2009-07-23
EP2225256A2 (en) 2010-09-08
MA31867B1 (fr) 2010-11-01
CN101878221A (zh) 2010-11-03
AP2010005267A0 (en) 2010-06-30
BRPI0820447A2 (pt) 2015-05-26
US20090227548A1 (en) 2009-09-10
UY31496A1 (es) 2009-07-17
AR069490A1 (es) 2010-01-27
SV2010003580A (es) 2011-03-23
GT201000153A (es) 2012-04-27
CO6280401A2 (es) 2011-05-20
AU2008331187A1 (en) 2009-06-04
TW200930378A (en) 2009-07-16
TN2010000230A1 (fr) 2011-11-11
KR20100074306A (ko) 2010-07-01
EP2225256B1 (en) 2013-01-09
PA8805801A1 (es) 2009-07-23
NI201000090A (es) 2010-10-04
JP2011505350A (ja) 2011-02-24
US20140336160A1 (en) 2014-11-13
JP4686650B2 (ja) 2011-05-25
NZ585434A (en) 2012-06-29
DOP2010000161A (es) 2010-07-15
ECSP10010209A (es) 2010-06-29
CN101878221B (zh) 2014-04-02
HK1144821A1 (en) 2011-03-11
ES2399945T3 (es) 2013-04-04
MX2010005861A (es) 2010-06-11
EA201070535A1 (ru) 2010-12-30
ZA201003439B (en) 2011-02-23
US8822439B2 (en) 2014-09-02
KR101295998B1 (ko) 2013-08-13
CA2706180C (en) 2012-10-23

Similar Documents

Publication Publication Date Title
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
MX2012006964A (es) Nuevos antagonistas del receptor ccr2 y usos de los mismos.
CL2017002650A1 (es) Compuestos novedosos
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CL2012001971A1 (es) Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras.
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
CL2007002099A1 (es) Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
MX2011009847A (es) Agentes antihelminticos y su uso.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
EA020330B3 (ru) Хиназолиновые соединения
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares